Advancing pharmaceutical research through innovative receptor agonist compounds and next-generation drug development
Explore Our ResearchDeveloping selective receptor agonists for therapeutic applications in metabolic disorders, neurological conditions, and cardiovascular health.
Advanced screening and optimization of novel agonist compounds with enhanced efficacy, selectivity, and safety profiles.
Comprehensive clinical trial programs evaluating agonist therapeutics across multiple disease indications and patient populations.
AGN-101: Selective β2-adrenergic receptor agonist for respiratory conditions
AGN-202: GLP-1 receptor agonist for metabolic syndrome
AGN-303: Novel dopamine receptor agonist for Parkinson's disease
The Agonists is a biopharmaceutical research company dedicated to discovering and developing innovative receptor agonist compounds. Our multidisciplinary team combines expertise in medicinal chemistry, pharmacology, and clinical development to advance therapeutics that address unmet medical needs. Through rigorous scientific inquiry and strategic partnerships, we're transforming the landscape of agonist-based medicine.